2012
Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Rocco AD, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M.
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZITER3 trial of the Intergruppo Italiano Linfomi.
Leuk Lymphoma. 2012 Apr; 53(4):581-8 Epub 2011 Nov 15.
2011
Ladetto M.
The adulthood of MRD detection in MCL
Blood 2010 Apr 22; 115(16): 3180-3181
Mian M, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M,Devizzi L, Gianni AM, Busetto M, Berti E, Martinelli G, Tsang RW, Ferreri AJ, Pinotti G, Pogliani E, Zucca E, Cortellazzo S.
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)
Annals of Hematology 2011 Apr; 90(4): 401-408
Cortelazzo S. Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E.
Clinical activity of bortezomib in relapsed/refractory malt lymphomas: results of a phase II study of the international extranodal lymphoma study group (IELSG)
Annals of Oncology 2011; 22(3): 689-695
Mian M, Gaidano G, Conconi A, Tsang R, Gospodarowicz MK, Rambaldi A, Rossi A, Oldani E, Federico M, Luminari S, bellei M, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Lopez-Guillermo A, Busetto M, Cavalli F, Zucca E, Cortellazzo S.
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi.
Leuk Lymphoma. 2011 May; 52(5): 823-32 Epub 2011 feb 21
Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E.
First line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
J Clin Onco, 2011 Jul 10; 29(20): 2766-2772
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi.
ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned.
N Engl J Med. 2011 Jul 21; 365(3): 203-12
Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragrasso A, Gobbi PG, Liberati AM, Federico M.
R-CHOP vs R-miniCEOP for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma. Results from the ANZITER3 trial of the Intergruppo Italiano Linfomi (IIL).
Leuk Lymphoma. 2011 Sep 7
Chiesesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi.
J Clin Onco, 2011 Nov 10; 29(32): 4227-33 Epub Oct 11
Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Rocco AD, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M.
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab for the initial treatment of elderly ‘fit’ patients with diffuse large large b-cell lymphoma: results from the ANZITER3 trial of the Intergruppo Italiano Linfomi.
Leuk Lymphoma. 2011 Nov 15 [Epub ahead of print]
Ferrari A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L
Fludarabine, cyclophospamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: Phase 2 study of the Italian Lymphoma Foundation.
Cancer, 2011 Dec 16 [Epub ahead of print]
2010
Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, Balleari E, Musto P, Neri S, Aloe Spiriti M A, Cox M C.
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never ending story.
Annals of Oncology 2010 21 (7): 1486-1491doi:10,1083/annonc/mdp531
Ladetto M.
The adulth of MRD detection in MCL
Blood 2010 Apr 22; 115(16): 3180-3181
2009
Carella AM, Bellei M, Brice P, Gisselbrecht C, Visani G, Colombat P, Fabbiano F, Donelli A, Luminari S, Feugier P, Browett P, Hagberg H, Federico M.
High-dose therapy and autologus stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results.
Haematologica 2009 January; 94(1):146-8
Meignan M, Gallamini A, Haioun C.
Report on the first international workshop on interim-PET scan in lymphoma.
Leuk Lymphoma, 2009, Aug; 50(8):1257-60
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortellazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Ce’ligny P.
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognosti Factor Project.
J Clin Onco, 2009 Sep 20; 27(27):4555-62
Brusamolino E.
First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions.
Haematologica 2009 September; 94(9):1194-1198
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; on behalf of the International Extranodal Lymphoma Study Group (IELSG).
High-dose cytarabine plus high-dose methotrexate versus high-dose metotrexate alone in patients with primary CNS lymphoma: a randomized phase 2 trial.
Lancet. 2009 Oct 31; 374(9700): 1512-20
2008
Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortellazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an over-all survival advantage.
Blood 2008 Apr 15; 111(8): 4004-13. Epub 2008 Jan 31
Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati A M, Gavarotti P, Levis A; on behalf of the Intergruppo Italiano Linfomi (IIL).
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin’s lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
Annals of Oncology 2008 Apr; 19(4): 763-768. Epub 2008 Jan 6
2007
Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M; Intergruppo Italiano Linfomi.
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease.
Br J Haematol. 2007 Jan; 136 (2): 301-4
Merli F, Bertini M, Luminari S, Mozzana R, Botto B, Liberati AM, Baldini L, Cabras G, Vito FD, Orsucci L, Naglieri E, Polimeno G, Marcheselli L, Pennese E, Vitolo U, Federico M, Gallo E.
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma.
Leuk Lymphoma. 2007 Feb; 48(2):367-73
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D’ Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A.
Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study.
J Clin Oncol. 2007 Aug 20; 25(24):3746-52. Epub 2007 Jul 23
Rigacci L, Vitolo U, Nassi L, Merli F, Gallamini A, Pregno P, Alvarez I, Salvi F, Sancetta R, Castagnoli A, Versari A, Biggi A, Gregianin M, Pelosi E, Chisesi T, Bosi A, Levis A; On behalf of Intergruppo Italiano Linfomi.
Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.
Ann Hematol. 2007 Dec; 86(12):897-903. Epub 2007 Aug 16
2006
P. G. Gobbi,. C. Broglia, A. Levis, A. La Sala, F. Valentino, T. Chisesi, S. Sacchi, F. Corbella, L. Cavanna, E. Iannitto, V. Pavone, S. Molica, G. R. Corazza and M. Federico.
MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin’s Lymphoma:10-Year Results, Late Toxicity and Second Tumors.
Clinical Cancer Res 2006; 12(2) January 15, 2006, 529-535
A. Gallamini, L. Rigacci, F. Merli, L. Nassi, A. Bosi, I. Capodanno, S. Luminari, U. Vitolo, R. Sancetta, E. Iannitto, L. Trentin, C. Stelitano, S. Tavera, A. Biggi, A. Castagnoli, A. Versari, M. Gregianin, E. Pelosi, P. Torchio, A. Levis.
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease.
Haematologica. 2006 Apr; 91(4): 475-481
L. Pagano, A. Gallamini, G. Trapè, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, A. Nosari, E. Di Bona, M.E. Tosti, M. C. Petti, P. Falcucci, M. Montanaro, A. Pulsoni, L. M. Larocca, G. Leone for the Intergruppo Italiano Linfomi.
NK/T – cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey.
Annals of Oncology 2006 May; 17(5): 794-800
Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortellazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Vito F, Iannitto E, for the Intergruppo Italiano Linfomi.
Splenic marginal zone lymphoma: a prognostic model for clinical use.
Blood, 15 june 2006, Vol. 107, No 12, pp 4643-4649
Luminari S, Federico M.
Prognosis of follicular lymphomas.
Haematol Oncol. 2006 Jun;24(2):64-72. Review
Gobbi PG, Levis A, Chisesi T, Pavone V, Federico M, Brugiatelli M (on behalf of the Intergruppo Italiano Linfomi).
Unlike ABVD and MOPPEBVCAD, Stanford V chemotherapy does not tolerate the combination with a reduced and conditioned radiotherapy for the treatment of advanced Hodgkin lymphoma. Am J Oncol Rev, 5: 356-359, 2006
Anni precedenti: dal 2005 al 2000
D. Vallisa, P. Bernuzzi, L. Arcaini, S. Sacchi, V. Callea, R. Marasca, A. Lazzaro, E. Trabacchi, E. Anselmi, A. L. Ascari, C. Moroni, r. Bertè, M. Lazzarino, L. Capanna.
Role of anti-hepatitis C Virus (HCV) treatment in HCV-related, low-grade, B-cell, Non Hodgkin’s Lymphoma: a multicenter italian experience.
Journal of Clinical Oncology, Vol 23, No 3 (january 20), 2005: pp. 468-473
Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, Boccomini C, Brugiatelli M, Calvi R, Ciccone G, Genua A, Labmertenghi Deliers G, Levis A, Parvis G, Pavone E, Salvi F, Sborgia M, Gallo E.
High dose sequential chemotherapy with autologus transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial.
Haematologica. 2005 Jun; 90(6): 793-801
P. G. Gobbi, A. Levis, T. Chisesi, C. Broglia, U. Vitolo, C. Stelitano, V. Pavone, L. Cavanna, G. Santini, F. Merli, M. Liberati, L. Baldini, G. Lambertenghi Deliers, E. Angelucci, R. Bordonaro, M. Federico.
ABVD versud Modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate – and advanced – stage Hodgkin’s Lymphoma: final results of a multicenter randomized trial by Intergruppo Italiano Linfomi.
Journal of Clinical Oncology – 2005 Dec 20; 23(36): 9198-207. Epub 2005 Sep 19
Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F; Intergruppo Italiano Linfomi (IIL) study.
VEPEMB in elderly Hodgkin’s limphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.
Ann Oncol. 2004 Jan; 15(1): 123-8
A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto, F. Zaja, S. Cortellazzo, L. Rigacci, L. Devizzi, G. Todeschini, G. Santini, M. Brugiatelli, M. Federico for the Intergruppo Italiano Linfomi.
Pheripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic mode from retrospective multicenter clinical study.
Blood. 2004 Apr 1; 103(7): 2474-2479. Epub 2003 Nov 26
Merli F, Bertini M, Luminari S, Mozzana R, Berte R, Trottini M, Stelitano C, Botto B, Pizzuti M, Quintana G, De Paoli A, Federico M; Intergruppo Italiano Linfomi.
Quality of life assestment in elderly patients with aggressive non-Hodgkin’s Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
Haematologica. 2004 Aug; 89(8): 973-8
G. Todeschini, S. Secchi, E. Morra, U. Vitolo, E. Orlandi, E. Pasini, E. Gallo, A. Ambrosetti, C. Tecchio, C. Tarella, A. Gabbas, A. Gallamini, L. Gargantini, M. Pizzuti, G. Fioritoni, L. Gottin, G. Rossi, M. Lazzarino, F. Menestrina, M. Paulli, M. Palestro, M. G. Cabras, F. Di Vito and G. Pizzolo.
Primary mediastrinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
British Journal of Cancer (2004) 90, 372-376
Céligny S.P, Roy P, Colombat P, White J, Armitage O.J, Arranz-Saez R, Au Wing Y, Bellei M, Brice P, Caballero D, Coiffier B, Conode Garcia E, Doyen C, Federico M, Fisher Richard I, Garcia Conde Javier F, Guglielmini C, Hagenbeek A, Haïoun C, LeBlanc M, T. Lister A, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, J. Proctor S, Rohatiner A, Smith P, Souberyran P, Tilly H, Vitolo U, Zinzani P.L., Zucca E and Monserrat E.
Follicular Lymphoma International prognostic Index.
Blood. 2004, Sep 1; 104(5): 1258-1265
Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, Lazzaro A, Orsucci L, Ilariucci F, Sacchi S, Vitolo U, Federico M.
Clinical relevance of immunphenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas.
Cancer. 2004 Oct; 101(7): 1601-8
Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortellazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarolo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser O, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, levis A.
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
Cancer. 2003 Jun 1; 97(11): 2748-59
M. Federico, M. Bellei, P. Brice, M. Brugiatelli, A. Nagler, C. Gisselbrecht, L. Moretti, P. Colomat, S. Luminari, F. Fabbiano, N. Di Renzo, A. Goldstone and A. M. Carella for the EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial.
High-dose therapy and autologus stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy.
Journal of Clincal Oncology, 21(2): 2320-2325, 2003
L. Rigacci, M. Federico, M. Martinelli, P.L. Zinzani, L. Cavanna, G. Bellesi, F. Merli, R. Alterini, M.T. Petrucci, M. Tani, A.M. Liberati, U. Vitolo, V. Pavone, A. Cuneo, T. Chisesi, M. Brugiatelli on behalf of the Intergruppo Italiano Linfomi.
The role of anthracyclines in combination chemtotherapy for the treatment follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
Leuk Lymphoma. 2003 Nov; 44(11): 1911-7
Levis A, Pietrasanta D, Anselmo AP, Ambrosetti A, Bertini M.
Treatment of elderly Hodgkin’s lymphoma patients. The expericence of the Italian Lymphoma Intergroup.
Tumori. 2002 Jan-Feb; 88 (1 Suppl 1): S29-31
Chisesi T, Federico M, Levis A, Deliers GL, Gobbi PG, Santini G, Luminari S, Linfomi MB; Intergruppo Italiano Linfomi.
ABVD versus Stanford V versus MEC in unfavourable Hodgkin’s Lymphoma: results of a randomized trial.
Ann. Oncol. 202; 13 Suppl 1: 102-6
P.L. Zinzani, M. Martelli, M. Bertini, A. M. Gianni, L. Devizzi, M. Federico, G. Pangalis, J. Michelis, E. Zucca, M. Cantonetti, S. Cortellazzo, A. Wotherspoon, A. J. M. Ferreri, F. Zaja, F. Lauria, A. De Renzo, A. Liberati, B. Falini, M. Balzarotti, A. Calderoni, A. Zaccaria, P. Gentilini, P.P. Fattori, E. Pavone, M. K. Angelopoulou, L. Alinari, M. Brugiatelli, N. Di Renzo, F. Bonifazi, A. S. Pileri, F. Cavalli for the International Extranodal Lymphoma Study Group (IELSG).
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective study on 426 previously untreated patients.
Haematologica 2002; 87: 1258-1264
C. Guglielmi, M. Martelli, M. Federico, P.L. Zinzni, U. Vitolo, G. Bellesi, G. Santini, C. Tarella, F. Zallio, P. Pregno, N. Di Renzo, L. Resegotti.
Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.
Haematologica 2001; Sep 86(9): 941-950
Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Ruspoli S, Di Raimondo F, Merli F, Liso V, Tablio A, Saglio G, Vinci G, brugiatelli M, Dastoli G.
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hogkin’s lymphoma.
Haematologica 2001; Sep 86(9): 951-8
M. Federico, U. Vitolo, P.L. Zinzani, T. Chisesi, V. Clo, G. Bellesi, M. Magagnoli, M. Liberati, C. Boccomini, P. Niscola, V. Pavone, A. Cuneo, G. Santini, M. Brugiatelli, L. Baldini, L. Rigacci, L. Resegotti for the Intergruppo Italiano Linfomi.
Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases.
Blood. 2000 Feb 1; 95 (3): 783-789
